Dutch-based Ansana bags €1.5M to make hospital surgeries safer with its smart sterilisation technology

Dutch-based Ansana raises funds to advance SteriWatch, its sterilisation system designed to enhance hospital workflows and patient safety.

Maastricht-based Ansana, a health tech company based in the Netherlands, has raised €1.5M in a Seed round of funding.

The investment came from NLC Health Ventures, Healthliant Ventures, BGO Ventures, and a group of private investors.

Margarida Lopes at NLC Health Ventures says, “Ansana’s technology tackles a critical challenge in hospitals by ensuring sterile instruments while also driving efficiency and sustainability. This is exactly the type of innovation we want to see reaching patients and the kind of solution we aim to invest in through our funds.”

A smart sterilisation technology for healthcare

Founded in 2022, Ansana is developing and marketing a sterilisation technology for the healthcare and pharmaceutical sectors. 

The technology consists of an intelligent sterilisation container designed to ensure sterility and traceability in hospital and industrial workflows. It reduces patient risk, lowers costs, and improves operational flows while minimising the ecological impact of sterilisation processes.

Ansana is introducing SteriWatch, a sterilisation system that integrates sensors and real-time track-and-trace capabilities into containers to maintain sterility and full traceability across the lifecycle of surgical instruments.

The company’s mission is to improve patient safety and make healthcare processes more sustainable and affordable. Ansana aims to set a standard in sterilisation process management and control within healthcare and pharmaceutical operations.

SteriWatch combines a medical device with integrated sensors, track-and-trace technology, and data modules. The platform supports quality release, scheduling, inventory management, and operating room service planning. 

It helps maintain instrument sterility, reduces the incidence of surgical site infections, and enables digital workflows that optimise instrument turnaround and reduce inventory needs. By removing consumables from the sterilisation process, SteriWatch also contributes to lowering the carbon footprint of healthcare services.

Capital utilisation

The funding will support the development of Ansana’s minimum viable product, obtain ISO 13485 certification, and launch pilot projects in clinical settings. These steps are intended to prepare the company for technology scaling and commercial rollout.

Partnership with Healthliant Ventures

Ansana’s current investment builds on its partnership with Healthliant Ventures, where SteriWatch will be piloted in surgical instrument reprocessing workflows.

Healthliant Ventures, the innovation division of Tanner Health System, partners with startups to validate, co-develop, and scale healthcare technologies. With access to Tanner’s hospitals and physician network, it provides a real-world environment to accelerate adoption across health systems.

Steve West, MD at Healthliant Ventures, mentions, “Partnering with Ansana underscores our commitment to supply the sterilisation departments from Tanner Health System with smart technology that enhances patient safety and operational efficiency. SteriWatch promises to streamline reprocessing, reduce infection risk for patients, support sustainability and improve surgical workflows across our system.”

Dominique Surinx, CEO and co-founder of Ansana, adds, “Next to the immediate patient and operational benefits, SteriWatch supports the strategic growth objectives of healthcare systems and hospital groups. This enables a network and centralised approach towards surgical instrument reprocessing. Further, it installs the basis for continuous and long-term process improvements.”

“The team is so excited to continue our fast development and impact positively on patients and healthcare workers globally.”